This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why LabCorp (LH) Could Beat Earnings Estimates Again
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Here's Why LabCorp (LH) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain LabCorp (LH) Stock For Now
by Zacks Equity Research
Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).
LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit
by Zacks Equity Research
The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.
Labcorp (LH): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Labcorp (LH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
by Zacks Equity Research
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
by Zacks Equity Research
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
A faster-than-expected recovery in base business and stabilized demand for COVID-19 testing instill optimism in Quest Diagnostics (DGX).
4 Medical Device Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.
Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.
Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.
Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
by Zacks Equity Research
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up
by Zacks Equity Research
Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.